Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Algeta reports updated data from phase III ALSYMPCA trial

Feb. 13, 2012

Sanofi prepares novel fibroblast growth factor receptor antagonists

Feb. 13, 2012

TOCA therapy increases survival in models of brain cancer

Feb. 13, 2012

FDA advisory committee issues vote on Dacogen sNDA

Feb. 10, 2012

Jubilant and Endo Pharmaceuticals nominate anticancer candidate

Feb. 10, 2012

Eribulin mesilate added to chemotherapy in patients with bladder cancer

Feb. 10, 2012

Sanofi synthesizes new fibroblast growth factor receptor antagonists

Feb. 10, 2012

Prometheus Laboratories enters collaboration with leading pharmaceutical company

Feb. 9, 2012

RedHill receives approval from Health Canada to begin RHB-102 trial

Feb. 9, 2012

Detailed results presented of phase III regorafenib study

Feb. 9, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...